Latest Novocure News & Updates

See the latest news and media coverage for Novocure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Novocure

Oncology medical device company

novocure.com
Headquarters
Baar, Switzerland
Founded year
2000
Company type
Public company
Number of employees
1,500–5,000

Last updated

Latest news about Novocure

In short: Novocure faced a stock drop after its TRIDENT glioblastoma trial failed, though it secured FDA approval for Optune Pax in pancreatic cancer.

Company announcements

Novocure

Novocure reports Q1 2026 financial results

Net revenues reach $174 million, up 12% year-over-year. Optune Pax gains FDA approval and launches for pancreatic cancer. Active patients total 4,791 globally.

Novocure

Novocure announces positive topline results from PANOVA-4 trial

The Phase 2 trial met its primary endpoint with 74.4% disease control rate in metastatic pancreatic cancer patients treated with TTFields plus chemotherapy, exceeding historical control. Novocure plans future presentations.

Unlock all announcements with a

Media coverage

Aktien-Check

NovoCure stock: Optune Pax approved

NovoCure stock rises over 13 percent to 15.41 euros on Thursday. The medical technology specialist benefits from several positive developments from the clinical...

Unlock all articles with a

Never miss news about Novocure

Track Novocure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.